Johnson & Johnson posts $25.3 billion Q2 sales
Share
- Johnson & Johnson reported $25.3 billion in second-quarter sales, representing a 6.6% reported growth compared to the prior year.
- The company recorded a second-quarter adjusted earnings per share of $2.90 alongside a reported earnings per share of $2.27.
- Management increased its full-year 2026 guidance, stating the company expects reported sales of $101.1 billion driven by operational performance.
Johnson & Johnson (NYSE:JNJ) reported second-quarter sales of $25.3 billion alongside a reported earnings per share of $2.27.
This quarterly sales figure represents a reported 6.6% increase and an operational growth of 5.6% compared to the prior year.
"With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history," said Johnson & Johnson Chairman and Chief Executive Officer Joaquin Duato.
The company secured regulatory approvals for treatments including TREMFYA and CAPLYTA while raising its full-year adjusted earnings per share guidance by $0.13 to $11.68.
The business continues to advance its medical technology and pharmaceutical pipeline with ongoing clinical data reviews for the RYBREVANT FASPRO and TALVEY systems.
Management stated that the company expects its full-year 2026 reported sales to reach $101.1 billion, reflecting a targeted 7.3% growth rate at the midpoint.
